

Program

8th Cancer Crosslinks 2016

January 14, 2016 – Ullernchausséen 64-66, entrance 2b, Oslo Cancer Cluster Innovation Park

08:30h - 09:15h REGISTRATION & COFFEE	
The transversal impact of new treatments in Oncology and Hematology: tumor microenvironment, novel concepts, combinations and study design	
Chairperson: Anna K. Winge-Main; Senior Oncologist, Department of Oncology, Oslo University Hospital	
09:15h - 09:20h	Welcome and outlook for 2016 - Oslo Cancer Cluster
09:20h - 09:30h	Introduction by Dr. Anna K. Winge-Main
09:30h - 10:30h	Opening Keynote: "PD-1 cancer immunotherapy" <i>Prof. Gordon J. Freeman; Division of Hematologic Malignancies, Department of Medical Oncology; Dana-Farber Cancer Institute & Harvard Medical School, Boston, USA</i>
10:30h - 11:00h	<ul style="list-style-type: none"> ▪ Case Study: Immunotherapy in NSCLC <i>Dr. Åslaug Helland; Senior Oncologist, Dept. of Oncology, Oslo University Hospital and Group leader, Institute for Cancer Research Oslo University Hospital</i> ▪ Case Study: PD-1 in Lymphoma <i>Dr. Alexander Fosså; Senior Oncologist, Dept. of Oncology, Oslo University Hospital</i>
11:00h - 11:30h COFFEE & NETWORKING BREAK	
Chairpersons: <i>Dr. Fredrik Schjesvold; Senior Consultant Hematology at Bærum hospital, Head of Clinical Plasma Cell Research at Oslo University Hospital and Dr. Jon-Amund Kyte; Senior Oncologist at Oslo University Hospital</i>	
11:30h - 11:40h	Introduction by Fredrik Schjesvold and Jon Amund Kyte
11:40h - 12:30h	International Keynote: "CAR T-cell Treatment of B-Cell Malignancies – with an overview of current treatment options in leukemia" <i>Prof. Renier Brentjens, MD, PhD; Chief, Cellular Therapeutics Center & Associate Professor Memorial Sloan-Kettering Cancer Center; New York, USA</i>
12:30h - 13:00h	<ul style="list-style-type: none"> ▪ "Harnessing adaptive natural killer cells in cancer immunotherapy" <i>Prof. Karl-Johan Malmberg; Group Leader, Dept. of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital</i> ▪ "A murine model for development of immunotherapy against multiple myeloma" <i>Dr. Anders Tveita; Centre for Immune Regulation (CIR), University of Oslo</i>
13:00h - 14:00h LUNCH & NETWORKING BREAK	
14:00h - 14:50h	International Keynote: "The role of the T cell-inflamed and non-T cell-inflamed tumor microenvironment for immunotherapy" <i>Dr. Stefani Spranger; Department of Pathology, The Ben May Department for Cancer Research, University of Chicago, USA</i>
14:50h - 15:30h	"Defining treatment strategies in 2016: Opportunities and Challenges" Panel Discussion with International and Norwegian speakers <i>Moderated by: Anna Winge-Main and Alexander Fosså</i>
15:30h - 15:45h COFFEE & NETWORKING BREAK	
Closing Session: The patient's perspective (this part will be in Norwegian)	
15:45h - 16:00h	Introduction by Dr. Åslaug Helland, Oslo University Hospital
16:00h - 16:30h	The patient perspective: <i>Kjell V. Larsen</i>
16:30h - 19:30h NETWORKING EVENING WITH TAPAS & WINE	